NICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe AD in the NHS England

Almirall announced that the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe atopic dermatitis in the NHS England.

Lebrikizumab is indicated for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate-to-severe AD, who are candidates for systemic therapy. The treatment was approved by the European Commission and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in December 2023.

“The NICE recommendation for lebrikizumab for eligible people 12 years and over suffering with moderate-to-severe AD in England is testament to the benefits this treatment can bring to patients due to its demonstrated efficacy, with 4-weekly maintenance dosing and an acceptable safety profile," Jorgen Damsbo, General Manager at Almirall, UK, said in a company news release. "This is well aligned with our company purpose to transform the patient's world by helping them realize their hopes and dreams for a healthy life," 

Lebrikizumab is a monoclonal antibody that binds the cytokine IL-13 with high affinity to specifically prevent the formation of the IL-13Rα1/IL-4Rα heterodimer complex and subsequent signalling, thus inhibiting the biological effects of IL-13. Therefore, inhibition of the IL-13 signalling is expected to be of benefit in diseases in which IL-13 is a key contributor to the disease pathogenesis.